157 related articles for article (PubMed ID: 23242062)
1. Usefulness of 18F-FDG PET/CT in an unusual case of solid-pseudopapillary pancreatic tumor in childhood with aggressive behavior.
Treglia G; Caporale N; Rufini V; Callea F; Locatelli F; Giordano A
Clin Nucl Med; 2013 Jan; 38(1):e35-7. PubMed ID: 23242062
[TBL] [Abstract][Full Text] [Related]
2. Comparison of F-18-FDG PET/CT findings between pancreatic solid pseudopapillary tumor and pancreatic ductal adenocarcinoma.
Kim YI; Kim SK; Paeng JC; Lee HY
Eur J Radiol; 2014 Jan; 83(1):231-5. PubMed ID: 24290142
[TBL] [Abstract][Full Text] [Related]
3. FDG PET/CT findings of solid pseudopapillary tumor of the pancreas with CT and MRI correlation.
Dong A; Wang Y; Dong H; Zhang J; Cheng C; Zuo C
Clin Nucl Med; 2013 Mar; 38(3):e118-24. PubMed ID: 23354028
[TBL] [Abstract][Full Text] [Related]
4. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in the characterization of pancreatic masses: experience from tropics.
Santhosh S; Mittal BR; Bhasin D; Srinivasan R; Rana S; Das A; Nada R; Bhattacharya A; Gupta R; Kapoor R
J Gastroenterol Hepatol; 2013 Feb; 28(2):255-61. PubMed ID: 23278193
[TBL] [Abstract][Full Text] [Related]
5. Utility of contrast-enhanced FDG-PET/CT in the clinical management of pancreatic cancer: impact on diagnosis, staging, evaluation of treatment response, and detection of recurrence.
Asagi A; Ohta K; Nasu J; Tanada M; Nadano S; Nishimura R; Teramoto N; Yamamoto K; Inoue T; Iguchi H
Pancreas; 2013 Jan; 42(1):11-9. PubMed ID: 22699206
[TBL] [Abstract][Full Text] [Related]
6. A rare case of ectopic adrenocorticotropic hormone syndrome caused by a metastatic neuroendocrine tumor of the pancreas detected by 68Ga-DOTANOC and 18F-FDG PET/CT.
Treglia G; Salomone E; Petrone G; Giaccari A; Rindi G; Rufini V
Clin Nucl Med; 2013 Jul; 38(7):e306-8. PubMed ID: 23486330
[TBL] [Abstract][Full Text] [Related]
7. Nonfunctioning endocrine pancreatic tumor examined with 18F-FDG PET/CT.
Toshikuni N; Kai K; Fujisawa M
Ann Nucl Med; 2008 Feb; 22(2):133-7. PubMed ID: 18311538
[TBL] [Abstract][Full Text] [Related]
8. 18F-FDG PET/MR in an Atypical Pediatric Solid Pseudopapillary Pancreatic Tumor.
Cavaliere A; Giraudo C; Zuliani M; Cecchin D; Quaia E
Clin Nucl Med; 2019 Sep; 44(9):e522-e523. PubMed ID: 31274565
[TBL] [Abstract][Full Text] [Related]
9. Hyperaccumulation of (18)F-FDG in order to differentiate solid pseudopapillary tumors from adenocarcinomas and from neuroendocrine pancreatic tumors and review of the literature.
Guan ZW; Xu BX; Wang RM; Sun L; Tian JH
Hell J Nucl Med; 2013; 16(2):97-102. PubMed ID: 23687644
[TBL] [Abstract][Full Text] [Related]
10. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
[TBL] [Abstract][Full Text] [Related]
11. Impact of F18-fluorodeoxyglycose positron emission tomography/computed tomography on the management of resectable pancreatic tumours.
Yao J; Gan G; Farlow D; Laurence JM; Hollands M; Richardson A; Pleass HC; Lam VW
ANZ J Surg; 2012 Mar; 82(3):140-4. PubMed ID: 22510123
[TBL] [Abstract][Full Text] [Related]
12. [18F]Fluorodeoxyglucose PET/Computed Tomography in Gastrointestinal Malignancies.
Donswijk ML; Hess S; Mulders T; Lam MG
PET Clin; 2014 Oct; 9(4):421-41, v-vi. PubMed ID: 26050945
[TBL] [Abstract][Full Text] [Related]
13. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
[TBL] [Abstract][Full Text] [Related]
14. Comment on: "Tumor aggressiveness and patient outcome in cancer of the pancreas assessed by dynamic 18F-FDG PET/CT".
Salavati A; Saboury B; Alavi A
J Nucl Med; 2014 Feb; 55(2):350-1. PubMed ID: 24323814
[No Abstract] [Full Text] [Related]
15. Reply: Comment on: "Tumor aggressiveness and patient outcome in cancer of the pancreas assessed by dynamic 18F-FDG PET/CT".
Dimitrakopoulou-Strauss A; Frenkel A; Epelbaum R
J Nucl Med; 2014 Feb; 55(2):351-2. PubMed ID: 24323815
[No Abstract] [Full Text] [Related]
16. Recurrent pancreatic carcinoma and cholangiocarcinoma: 18F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT).
Cameron K; Golan S; Simpson W; Peti S; Roayaie S; Labow D; Kostakoglu L
Abdom Imaging; 2011 Aug; 36(4):463-71. PubMed ID: 21465110
[TBL] [Abstract][Full Text] [Related]
17. ¹⁸F-FDG PET/CT imaging of the pancreas: spectrum of diseases.
Nguyen VX; Nguyen CC; Nguyen BD
JOP; 2011 Nov; 12(6):557-66. PubMed ID: 22072244
[TBL] [Abstract][Full Text] [Related]
18. Hypermetabolic lesions of the pancreas on FDG PET/CT.
Dong A; Dong H; Zhang L; Zuo C
Clin Nucl Med; 2013 Sep; 38(9):e354-66. PubMed ID: 23486316
[TBL] [Abstract][Full Text] [Related]
19. The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer.
Bang S; Chung HW; Park SW; Chung JB; Yun M; Lee JD; Song SY
J Clin Gastroenterol; 2006; 40(10):923-9. PubMed ID: 17063113
[TBL] [Abstract][Full Text] [Related]
20. The usefulness of (18)F-FDG PET/MRI fusion image in diagnosing pancreatic tumor: comparison with (18)F-FDG PET/CT.
Nagamachi S; Nishii R; Wakamatsu H; Mizutani Y; Kiyohara S; Fujita S; Futami S; Sakae T; Furukoji E; Tamura S; Arita H; Chijiiwa K; Kawai K
Ann Nucl Med; 2013 Jul; 27(6):554-63. PubMed ID: 23580090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
